Pasireotide beneficial in long-term treatment of Cushing’s disease
Use of long-acting pasireotide in the treatment of Cushing’s disease (CD) appears to be effective and safe, yielding sustained biochemical and clinical improvements, with a safety profile that is favourable and consistent with that reported during the first year of therapy, according to data from the open-label extension phase of a phase III study.